Overview
Primary hyperkinetic heart syndrome (PHHS) is characterized by symptoms of cardiac overactivity including palpitations, forceful heart action, increased arterial pulsations, and hemodynamic abnormalities such as elevated cardiac index and systolic ejection rates. 1Diagnosis
Clinical Symptoms: Palpitations, rapid and forceful heart action, increased arterial pulsations.
Physical Examination: Cardiac systolic murmur.
Hemodynamic Parameters: Elevated systolic arterial pressure (SAP), heart rate (HR), cardiac index (Ci), left ventricular mean systolic ejection rate index (MSEJR), and pre-ejection pressure-time index (delta P/delta t).
Recommended Tests: Echocardiography to assess left ventricular function and pressures. 1Management
First-Line Treatment: Propranolol (80-160 mg/day) effectively reduces symptoms and hemodynamic abnormalities.
Adjunctive Measures: Placebo substitution leads to symptom recurrence, highlighting the necessity of continued pharmacological management. 1Special Populations
No Specific Data Provided: The abstracts do not cover management in pregnancy, pediatrics, elderly, or comorbid conditions. 1Key Recommendations
Initiate propranolol therapy (80-160 mg/day) for symptomatic relief and hemodynamic stabilization in patients with primary hyperkinetic heart syndrome. (Evidence: Strong 1)
Monitor hemodynamic parameters including SAP, HR, cardiac index, and left ventricular ejection rates to assess treatment efficacy. (Evidence: Moderate 1)
Avoid discontinuation of propranolol without careful evaluation, as symptoms and hemodynamic abnormalities tend to recur upon placebo substitution. (Evidence: Weak 1)References
1 Guazzi M, Polese A, Magrini F, Fiorentini C, Olivari MT. Long-term treatment of hyperkinetic heart syndrome with propranolol. The American journal of the medical sciences 1975. link